keyword
MENU ▼
Read by QxMD icon Read
search

Invasive ovarian tumor platinum resistance

keyword
https://www.readbyqxmd.com/read/27743201/downregulation-of-foxo3-and-trim31-by-mir-551b-in-side-population-promotes-cell-proliferation-invasion-and-drug-resistance-of-ovarian-cancer
#1
Zhentong Wei, Yan Liu, Yishu Wang, Yandong Zhang, Qinghua Luo, Xiaxia Man, Feng Wei, Xiaowei Yu
Ovarian cancer (OVCa) stem cells are associated with tumor growth, metastasis, and recurrence, which are driving forces behind a majority of the OVCa-related mortality. This subpopulation of cancer cells are characterized by uncontrolled proliferation, high invasiveness, and resistance against the current platinum-based therapy. Thus, targeting OVCa cancer stem cells has been focused in recent therapeutic development. Isolation and purification of cancer stem cells are, however, challenging for the lack of sensitive and specific markers...
November 2016: Medical Oncology
https://www.readbyqxmd.com/read/27648354/paclitaxel-targets-vegf-mediated-angiogenesis-in-ovarian-cancer-treatment
#2
Bin Ai, Zhixin Bie, Shuai Zhang, Ailing Li
Ovarian cancer is one of the gynecologic cancers with the highest mortality, wherein vascular endothelial growth factor (VEGF) is involved in regulating tumor vascularization, growth, migration, and invasion. VEGF-mediated angiogenesis in tumors has been targeted in various cancer treatments, and anti-VEGF therapy has been used clinically for treatment of several types of cancer. Paclitaxel is a natural antitumor agent in the standard front-line treatment that has significant efficiency to treat advanced cancers, including ovarian cancer...
2016: American Journal of Cancer Research
https://www.readbyqxmd.com/read/27415751/anticancer-potential-of-diarylidenyl-piperidone-derivatives-ho-4200-and-h-4318-in-cisplatin-resistant-primary-ovarian-cancer
#3
Adam C ElNaggar, Uksha Saini, Shan Naidu, Ross Wanner, Millie Sudhakar, John Fowler, Masaki Nagane, Periannan Kuppusamy, David E Cohn, Karuppaiyah Selvendiran
We have previously developed a novel class of bi-functional compounds based on a diarylidenyl-piperidone (DAP) backbone conjugated to an N-hydroxypyrroline (-NOH; a nitroxide precursor) group capable of selectively inhibiting STAT3 activation, translocation, and DNA binding activity. HO-4200 and H-4318 are 2 such derivatives capable of inducing apoptosis in ovarian cancer cells through this mechanism and demonstrated efficacy in platinum resistant primary ovarian cancer cell populations and tumor tissues. The improved absorption and cellular uptake of HO-4200 by cancer cells was determined using optical and electron paramagnetic resonance spectrometry...
October 2, 2016: Cancer Biology & Therapy
https://www.readbyqxmd.com/read/27292260/elevated-stat3-expression-in-ovarian-cancer-ascites-promotes-invasion-and-metastasis-a-potential-therapeutic-target
#4
U Saini, S Naidu, A C ElNaggar, H K Bid, J J Wallbillich, K Bixel, C Bolyard, A A Suarez, B Kaur, P Kuppusamy, J Hays, P J Goodfellow, D E Cohn, K Selvendiran
Although activation of the STAT3 pathway has been associated with tumor progression in a wide variety of cancer types (including ovarian cancer), the precise mechanism of invasion and metastasis due to STAT3 are not fully delineated in ovarian cancer. We found that pSTAT3 Tyr705 is constitutively activated in patient ascites and ascites-derived ovarian cancer cells (ADOCCs), and the range of STAT3 expression could be very high to low. In vivo transplantation of ADOCCs with high pSTAT3 expression into the ovarian bursa of mice resulted in a large primary tumor and widespread peritoneal metastases...
June 13, 2016: Oncogene
https://www.readbyqxmd.com/read/27223082/tunneling-nanotube-formation-is-stimulated-by-hypoxia-in-ovarian-cancer-cells
#5
Snider Desir, Elizabeth L Dickson, Rachel I Vogel, Venugopal Thayanithy, Phillip Wong, Deanna Teoh, Melissa A Geller, Clifford J Steer, Subbaya Subramanian, Emil Lou
In this study, we demonstrated that hypoxic conditions stimulated an increase in tunneling nanotube (TNT) formation in chemoresistant ovarian cancer cells (SKOV3, C200).We found that suppressing the mTOR pathway using either everolimus or metformin led to suppression of TNT formation in vitro, verifying TNTs as a potential target for cancer-directed therapy. Additionally, TNT formation was detected in co-cultures including between platinum-resistant SKOV3 cells, between SKOV3 cells and platinum-chemosensitive A2780 cells, and between SKOV3 cells cultured with benign ovarian epithelial (IOSE) cells; these findings indicate that TNTs are novel conduits for malignant cell interactions and tumor cell interactions with other cells in the microenvironment...
July 12, 2016: Oncotarget
https://www.readbyqxmd.com/read/27170529/mechanistic-nanotherapeutic-approach-based-on-sirna-mediated-dj-1-protein-suppression-for-platinum-resistant-ovarian-cancer
#6
Canan Schumann, Stephanie Chan, Oleh Khalimonchuk, Shannon Khal, Vitaliya Moskal, Vidhi Shah, Adam W G Alani, Olena Taratula, Oleh Taratula
We report an efficient therapeutic modality for platinum resistant ovarian cancer based on siRNA-mediated suppression of a multifunctional DJ-1 protein that is responsible for the proliferation, growth, invasion, oxidative stress, and overall survival of various cancers. The developed therapeutic strategy can work alone or in concert with a low dose of the first line chemotherapeutic agent cisplatin, to elicit a maximal therapeutic response. To achieve an efficient DJ-1 knockdown, we constructed the polypropylenimine dendrimer-based nanoplatform targeted to LHRH receptors overexpressed on ovarian cancer cells...
May 26, 2016: Molecular Pharmaceutics
https://www.readbyqxmd.com/read/27100483/the-role-of-annexin-a4-in-cancer
#7
Houshan Yao, Chang Sun, Zhiqian Hu, Weijun Wang
Annexin A4 (ANXA4) is a member of the annexin family that binds to both calcium ions and phospholipids. Studies indicate that ANXA4 modulates membrane permeability and membrane trafficking, participates in cellular growth and apoptosis, enhances tumor invasion and promotes anti-tumor drug resistance. The overexpression of ANXA4 has been identified in various clinical epithelial tumors including: lung, gastric, colorectal, pancreatic, gallbladder, breast, renal, ovarian, laryngeal, and prostate cancers. In addition, upregulation and nuclear translocation of ANXA4 have been observed in the progression of colorectal cancer and ovarian serous carcinoma...
2016: Frontiers in Bioscience (Landmark Edition)
https://www.readbyqxmd.com/read/27049921/microrna-520g-promotes-epithelial-ovarian-cancer-progression-and-chemoresistance-via-dapk2-repression
#8
Jing Zhang, Lei Liu, Yunyan Sun, Jiandong Xiang, Dongmei Zhou, Li Wang, Huali Xu, Xiaoming Yang, Na Du, Meng Zhang, Qin Yan, Xiaowei Xi
The lack of efficient tumor progression and chemoresistance indicators leads to high mortality in epithelial ovarian cancer (EOC) patients. Dysregulated miR-520g expression is involved in these processes in hepatic and colorectal cancers. In this study, we found that miR-520g expression gradually increased across normal, benign, borderline and EOC tissues. High miR-520g expression promoted tumor progression and chemoresistance to platinum-based chemotherapy, and reduced survival in EOC patients. miR-520g upregulation increased EOC cell proliferation, induced cell cycle transition and promoted cell invasion, while miR-520g downregulation inhibited tumor-related functions...
May 3, 2016: Oncotarget
https://www.readbyqxmd.com/read/26899534/selective-inhibition-of-tumor-cell-associated-vacuolar-atpase-a2-isoform-overcomes-cisplatin-resistance-in-ovarian-cancer-cells
#9
Arpita Kulshrestha, Gajendra K Katara, Jordyn Ginter, Sahithi Pamarthy, Safaa A Ibrahim, Mukesh K Jaiswal, Corina Sandulescu, Ramayee Periakaruppan, James Dolan, Alice Gilman-Sachs, Kenneth D Beaman
Development of resistance to platinum compounds significantly hinders successful ovarian cancer (OVCA) treatment. In tumor cells, dysregulated pH gradient across cell membranes is a key physiological mechanism of metastasis/chemo-resistance. These pH alterations are mediated by aberrant activation of key multi-subunit proton pumps, Vacuolar-ATPases (V-ATPases). In tumor cells, its 'a2' isoform (V-ATPase-V0a2) is a component of functional plasma-membrane complex and promotes tumor invasion through tumor-acidification and immuno-modulation...
June 2016: Molecular Oncology
https://www.readbyqxmd.com/read/26679603/rad6-upregulation-promotes-stem-cell-like-characteristics-and-platinum-resistance-in-ovarian-cancer
#10
Ranganatha R Somasagara, Kaushlendra Tripathi, Sebastian M Spencer, David W Clark, Reagan Barnett, Lavanya Bachaboina, Jennifer Scalici, Rodney P Rocconi, Gary A Piazza, Komaraiah Palle
Ovarian cancer is the fifth most deadly cancer in women in the United States and despite advances in surgical and chemotherapeutic treatments survival rates have not significantly improved in decades. The poor prognosis for ovarian cancer patients is largely due to the extremely high (80%) recurrence rate of ovarian cancer and because the recurrent tumors are often resistant to the widely utilized platinum-based chemotherapeutic drugs. In this study, expression of Rad6, an E2 ubiquitin-conjugating enzyme, was found to strongly correlate with ovarian cancer progression...
January 15, 2016: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/26675258/mir-30a-inhibits-endothelin-a-receptor-and-chemoresistance-in-ovarian-carcinoma
#11
Rosanna Sestito, Roberta Cianfrocca, Laura Rosanò, Piera Tocci, Elisa Semprucci, Valeriana Di Castro, Valentina Caprara, Gabriella Ferrandina, Andrea Sacconi, Giovanni Blandino, Anna Bagnato
Drug resistance remains the major clinical barrier to successful treatment in epithelial ovarian carcinoma (EOC) patients, and the evidence of microRNA involvement in drug resistance has been recently emerging. Endothelin-1 (ET-1)/ETA receptor (ETAR) axis is aberrantly activated in chemoresistant EOC cells and elicits pleiotropic effects promoting epithelial-to-mesenchymal transition (EMT) and the acquisition of chemoresistance. However, the relationship between ETAR and miRNA is still unknown. Hence, in this study we evaluated whether dysregulation of miRNA might enhance ETAR expression in sensitive and resistant EOC cells...
January 26, 2016: Oncotarget
https://www.readbyqxmd.com/read/26458502/loss-of-autophagy-related-protein-beclin-1-may-define-poor-prognosis-in-ovarian-clear-cell-carcinomas
#12
Hiroshi Katagiri, Kentaro Nakayama, Sultana Razia, Kohei Nakamura, Emi Sato, Tomoka Ishibashi, Masako Ishikawa, Kouji Iida, Noriyoshi Ishikawa, Yoshiro Otsuki, Satoru Nakayama, Satoru Kyo
The aim of the present study was to clarify the role of autophagy in cisplatin (CDDP) sensitivity in OCCCs and the role of Beclin 1 in OCCC progression. Autophagy was measured using: i) western blot analysis of LC3 and p62 and ii) microscopic observation of GFP-LC3 puncta. Autophagy was suppressed using chloroquine and Beclin 1 siRNA. Surgical specimens were examined for Beclin 1 protein expression by immunohistochemistry. The correlations between the loss of Beclin 1 expression and clinicopathological characteristics, prognosis and chemosensitivity were investigated...
December 2015: International Journal of Oncology
https://www.readbyqxmd.com/read/26119935/yap-activation-protects-urothelial-cell-carcinoma-from-treatment-induced-dna-damage
#13
E Ciamporcero, H Shen, S Ramakrishnan, S Yu Ku, S Chintala, L Shen, R Adelaiye, K M Miles, C Ullio, S Pizzimenti, M Daga, G Azabdaftari, K Attwood, C Johnson, J Zhang, G Barrera, R Pili
Current standard of care for muscle-invasive urothelial cell carcinoma (UCC) is surgery along with perioperative platinum-based chemotherapy. UCC is sensitive to cisplatin-based regimens, but acquired resistance eventually occurs, and a subset of tumors is intrinsically resistant. Thus, there is an unmet need for new therapeutic approaches to target chemotherapy-resistant UCC. Yes-associated protein (YAP) is a transcriptional co-activator that has been associated with bladder cancer progression and cisplatin resistance in ovarian cancer...
March 24, 2016: Oncogene
https://www.readbyqxmd.com/read/25750333/cyclin-a-correlates-with-yb1-progression-and-resistance-to-chemotherapy-in-human-epithelial-ovarian-cancer
#14
Marek Cybulski, Bożena Jarosz, Andrzej Nowakowski, Witold Jeleniewicz, Elżbieta Kutarska, Wiesława Bednarek, Andrzej Stepulak
BACKGROUND: Cyclin A is a cell-cycle regulatory gene and its overexpression promotes tumor cell growth. Y-Box-binding protein 1 (YB1) is a transcription/translation factor involved in tumor growth, invasion, and drug resistance. We investigated whether an association exists between protein products of these genes in epithelial ovarian cancer (EOC) specimens and clinicopathological parameters, patient response and EOC sensitivity to platinum-based first-line chemotherapy. PATIENTS AND METHODS: Cyclin A and YB1 expression were analyzed by immunohistochemistry in 54 human primary EOC tissues...
March 2015: Anticancer Research
https://www.readbyqxmd.com/read/25695953/a-novel-neutralizing-antibody-targeting-pregnancy-associated-plasma-protein-a-inhibits-ovarian-cancer-growth-and-ascites-accumulation-in-patient-mouse-tumorgrafts
#15
Marc A Becker, Paul Haluska, Laurie K Bale, Claus Oxvig, Cheryl A Conover
The majority of ovarian cancer patients acquire resistance to standard platinum chemotherapy and novel therapies to reduce tumor burden and ascites accumulation are needed. Pregnancy-associated plasma protein-A (PAPP-A) plays a key role in promoting insulin-like growth factor (IGF) pathway activity, which directly correlates to ovarian cancer cell transformation, growth, and invasiveness. Herein, we evaluate PAPP-A expression in tumors and ascites of women with ovarian cancer, and determine the antitumor efficacy of a neutralizing monoclonal PAPP-A antibody (mAb-PA) in ovarian cancer using primary patient ovarian tumorgrafts ("Ovatars")...
April 2015: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/25482209/expression-of-mir-136-is-associated-with-the-primary-cisplatin-resistance-of-human-epithelial-ovarian-cancer
#16
Henan Zhao, Sha Liu, Guang Wang, Xian Wu, Yanfang Ding, Gordon Guo, Jiyong Jiang, Shiying Cui
MicroRNAs (miRNAs) are involved in regulating the response of cancer cells to various therapeutic interventions, yet their involvement in the chemoresistance of human epithelial ovarian cancer is not fully understood. We found that miR-136 was significantly downregulated in specimens from patients with chemoresistant epithelial ovarian cancer. In the present study, we aimed to clarify the role of miR-136 in regulating the chemoresistance of ovarian cancer. Thirty-four tumor bank specimens and 2 well-established human ovarian cancer cell lines, C13 and OV2008, were used...
February 2015: Oncology Reports
https://www.readbyqxmd.com/read/25457975/the-folate-receptor-as-a-rational-therapeutic-target-for-personalized-cancer-treatment
#17
REVIEW
Yehuda G Assaraf, Christopher P Leamon, Joseph A Reddy
Conventional cancer treatment modalities have several limitations including lack of sufficient efficacy, serious untoward toxicity, as well as innate and acquired drug resistance. In contrast, targeted imaging agents can identify patients with receptors overexpressed on the surface of cancer cells, thus allowing appropriate selection of patients for personalized treatment with a desirable targeted therapeutic. The folate receptor (FR) has been identified as a new molecularly targeted entity, which is highly overexpressed on the surface of a spectrum of solid tumor cells, including ovarian, kidney, lung, brain, endometrial, colorectal, pancreatic, gastric, prostate, testicular, bladder, head and neck, breast, and non-small cell lung cancer...
October 2014: Drug Resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy
https://www.readbyqxmd.com/read/25231401/preclinical-activity-of-the-liposomal-cisplatin-lipoplatin-in-ovarian-cancer
#18
Naike Casagrande, Marta Celegato, Cinzia Borghese, Maurizio Mongiat, Alfonso Colombatti, Donatella Aldinucci
PURPOSE: Cisplatin and its platinum derivatives are first-line chemotherapeutic agents in the treatment of ovarian cancer; however, treatment is associated with tumor resistance and significant toxicity. Here we investigated the antitumoral activity of lipoplatin, one of the most promising liposomal platinum drug formulations under clinical investigation. EXPERIMENTAL DESIGN: In vitro effects of lipoplatin were tested on a panel of ovarian cancer cell lines, sensitive and resistant to cisplatin, using both two-dimensional (2D) and 3D cell models...
November 1, 2014: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/25011213/cox-2-expression-pattern-is-related-to-ovarian-cancer-differentiation-and-prognosis-but-is-not-consistent-with-new-model-of-pathogenesis
#19
Magdalena Magnowska, Mikołaj Zaborowski, Paweł Surowiak, Ewa Nowak-Markwitz, Maciej Zabel, Marek Spaczyński
OBJECTIVE: Numerous studies suggest that cyclooxygenase-2 (COX-2) is overexpressed in cancer. Our objective was to investigate the relationship between COX-2 expression in ovarian carcinoma and clinicopathological factors. An emphasis was put on the association with the new pattern of tumorigenesis that divides tumors into type I--less aggressive, and type II--more aggressive one. The prognostic significance of COX-2 expression was evaluated. METHODS: Ovarian cancer tissues were obtained from 65 patients in FIGO III stage (23 with type I and 42 with type II ovarian cancer)...
May 2014: Ginekologia Polska
https://www.readbyqxmd.com/read/24860781/modeling-platinum-sensitive-and-resistant-high-grade-serous-ovarian-cancer-development-and-applications-of-experimental-systems
#20
REVIEW
Paula Cunnea, Euan A Stronach
High-grade serous ovarian cancer remains the most common sub-type of ovarian cancer and, characterized by high degrees of genomic instability and heterogeneity, is typified by a transition from early response to acquired resistance to platinum-based chemotherapy. Conventional models for the study of ovarian cancer have been largely limited to a set of relatively poorly characterized immortalized cell lines and recent studies have called into question the validity of some of these as reliable models. Here, we review new approaches and models systems that take into account advances in our understanding of ovarian cancer biology and advances in the technology available for their generation and study...
2014: Frontiers in Oncology
keyword
keyword
42281
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"